Aldeyra Therapeutics Inc (NASDAQ:ALDX) shot up 5.6% during trading on Tuesday . The stock traded as high as $7.23 and last traded at $6.21, with a volume of 467,354 shares. The stock had previously closed at $5.88.

Several brokerages have commented on ALDX. Stifel Nicolaus began coverage on shares of Aldeyra Therapeutics in a research report on Friday, July 1st. They set a “buy” rating and a $16.00 price target on the stock. Cowen and Company reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, May 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $13.13.

The company’s 50-day moving average is $5.89 and its 200 day moving average is $5.25. The company’s market capitalization is $36.35 million.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Wednesday, August 10th. The biotechnology company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.03. On average, analysts expect that Aldeyra Therapeutics Inc will post ($1.84) earnings per share for the current year.

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 700,000 shares of Aldeyra Therapeutics stock in a transaction dated Thursday, May 26th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $3,500,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.